SAM #75A50126R00002

BARDA seeks late-stage clinical development and procurement of 2-PAM autoinjectors for organophosphate poisoning treatment

BARDA, part of the Department of Health and Human Services, is seeking late-stage clinical development and procurement of 2-PAM autoinjectors for organophosphate poisoning treatment. - Government Buyer: - Biomedical Advanced Research and Development Authority (BARDA) - Office of Assistant Secretary for Preparedness and Response - Department of Health and Human Services - Products/Services Requested: - 2-PAM autoinjectors (drug/device combination product) - For treatment of organophosphate (OP) poisoning, including nerve agent exposure - Intended for both adult and pediatric populations - Procurement for Strategic National Stockpile (SNS) and CHEMPACK Program - Late-stage clinical development and regulatory approval services for 2-PAM autoinjectors - OEMs and Vendors: - No specific OEMs or vendors named in the notice - Unique/Notable Requirements: - Emphasis on regulatory approval and clinical development - Supply for national emergency preparedness programs (SNS and CHEMPACK) - Combination drug/device product for broad population use - Place of Performance and Delivery: - O’NEILL HOUSE OFFICE BUILDING, Washington, DC (contracting office) - Washington, DC (place of performance)

Description

This is a presoliciation notice for the following:

BARDA seeks late-stage clinical development, regulatory approval for 2-PAM autoinjectors (as a drug/device combination product) to treat organophosphate (OP) poisoning, including nerve agents, in adult and pediatric populations, and procurement of 2-PAM autoinjectors for the SNS/CHEMPACK Program.

View original listing